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Abstract
Background: The aim of the study was to investigate inflammation during the birch pollen season
in patients with rhinitis or asthma.
Methods: Subjects with birch pollen asthma (n = 7) or rhinitis (n = 9) and controls (n = 5) were
studied before and during pollen seasons. Eosinophils (Eos), eosinophil cationic protein (ECP) and
human neutrophil lipocalin were analysed.
Results: Allergic asthmatics had a larger decline in FEV1 after inhaling hypertonic saline than
patients with rhinitis (median) (-7.0 vs.-0.4%, p = 0.02). The asthmatics had a lower sesonal PEFR
than the rhinitis group. The seasonal increase in B-Eos was higher among patients with asthma
(+0.17 × 109/L) and rhinitis (+0.27 × 109/L) than among controls (+0.01 × 109/L, p = 0.01). Allergic
asthmatics and patients with rhinitis had a larger increase in sputum ECP (+2180 and +310 μg/L)
than the controls (-146 μg/L, p = 0.02). No significant differences in inflammatory parameters were
found between the two groups of allergic patients.
Conclusion:  Patients with allergic asthma and rhinitis have the same degree of eosinophil
inflammation. Despite this, only the asthmatic group experienced an impairment in lung function
during the pollen season.
Background
For many years, it has been known that allergic rhinitis
and bronchial asthma co-exist [1]. The majority of
patients with allergic asthma present with symptoms of
seasonal or perennial rhinitis and, in epidemiological
studies, rhinitis was found in up to 80%–100% of patients
with asthma [2,3]. Perennial rhinitis has also been found
to be a risk factor for asthma, independent of allergy [4]
and bronchial responsiveness [5], and, moreover, airway
remodelling is often present in non-asthmatic patients
with allergic rhinitis [6,7].
This link between the upper and lower airways is also sup-
ported by experimental data from allergen challenges.
Becky Kelly et al. have demonstrated a reduction in airway
function and an airway inflammatory response after local
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antigen challenge in atopic patients with or without
asthma [8]. Braunstahl and co-workers found that either
allergen provocation of the nose or segmental bronchial
provocation resulted in generalised airway inflammation
[9,10]. Murine animal studies provide further evidence of
the systemic link between nose and lungs [11,12]. Treat-
ment studies also point in the same direction. Pedersen et
al. [13] demonstrated an improvement in asthma in
patients treated with nasal steroids for their rhinitis and a
correlation between nasal eosinophils and a reduction in
FEV1 in patients with perennial allergic rhinitis has been
reported [14].
It is well established that the allergic inflammation in the
nasal and bronchial mucosa is characterised by tissue
eosinophilia. The allergic cascade and eosinophil migra-
tion is dependent on the expression of cytokines, chemok-
ines and adhesion molecules. The eosinophils release
their cytotoxic granule proteins as eosinophil cationic
protein (ECP), myeloperoxidase, eosinophil protein X
and eosinophil peroxides, causing airway damage and the
remodelling of the airway [15,16]. The role of neutrophils
in allergy and asthma has been discussed. According to
GINA (updated 2004), non-allergic and allergic asthma
are not distinct immunopathological entities. Recent
studies have, however, shown that airway inflammation
in chronic severe asthma displays an increased number of
neutrophils [17]. Human neutrophil lipocain, HNL,
which has been shown to be an entirely specific marker of
neutrophils [18], can be used to detect neutrophil
involvement.
There are still many questions to be resolved. Previous
studies have mainly been performed with high-dose aller-
gen challenge, which is not consistent with natural aller-
gen exposure, although a few studies have used very-low-
dose allergen challenge [19]. The aim of the present study
was to investigate the inflammatory reaction during natu-
ral allergen exposure during the birch pollen season in
birch-pollen-allergic patients with allergic rhinitis or aller-
gic asthma as the predominant symptoms. Our hypothe-
sis was that the location or the magnitude of the
inflammatory response explains to some extent why some
patients present with rhinitis and some with asthma, in
spite of having the same levels of specific IgE antibodies to
birch.
Methods
Patients
Sixteen birch-pollen-allergic patients were selected for the
study. All these patients were skin prick test positive to
birch pollen. None of the patients had symptoms during
the winter and/or were on regular treatment for rhinitis or
asthma outside the birch pollen season. Inhaled steroids
or nasal steroids were not allowed out of season nor dur-
ing the birch pollen season and none of the patients was
on any other regular medication during season. None of
the patients had smoked for the past ten years. Forced
expiratory volume in one second (FEV1) out of season was
more than 75% of predicted and FEV1/forced vital capac-
ity (FVC) more than 70% in all patients. All the patients
had doctors diagnosed seasonal allergic rhinitis or allergic
asthma, diagnosed by a lung physician and allergologist at
the allergy out-patient clinic. The patients with birch pol-
len induced asthma had a positive history of wheezing
and dyspnea during pollen season, whereas patients
whith allergic rhinitis all denied symptoms from the air-
ways.
Seven patients that had a diagnosis of allergic asthma and
reported having respiratory symptoms during the pollen
season even when neither having a cold nor having exer-
cised were categorised as having asthma as the predomi-
nant symptom (allergic asthma). Nine patients with a
diagnosis of allergic rhinitis but not allergic asthma and
having mainly eye and nose symptoms were categorised
as having rhinitis as the predominant symptom (allergic
rhinitis).
Control group
The control group consisted of five healthy, non-atopic,
never-smoking hospital employees and their relatives.
These persons had no allergic symptoms either outside or
during the birch pollen season. They were skin prick test
negative to nine standard allergens, including birch pol-
len, had no IgE antibodies to birch and had normal lung
function with an FEV1 of more than 80% of predicted.
Study design
The study included three visits to our out-patient clinic
and all the subjects were tested according to the procedure
presented in Table 1. Both the inclusion visit and the base-
line visit were performed out of season between Novem-
ber and February. When the pollen counts had reached
4,000 grains/m3 of air, the patients were told to start
recording their diary and, two to three weeks later, the sea-
son visit was made. The study was performed during the
birch pollen seasons in 2000 and 2002, due to the low
pollen count in 2001. Patients were included consecu-
tively, thus all patients were studied pre-season and dur-
ing season in the same year. The subjects were told to
avoid short-acting bronchodilators and anti-histamines
for 24 hours before the visit and nasal decongestants for
four hours before the visit.
Total pollen count
The number of airborne pollen particles was counted by
the Palynological Laboratory, Swedish Museum of Natu-
ral History, Stockholm, between 1 April and 31 May 2000
and 2002. Pollen recordings were made using a BurkhardClinical and Molecular Allergy 2007, 5:4 http://www.clinicalmolecularallergy.com/content/5/1/4
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seven-day recording volumetric spore trap [20]. The trap
was placed on the roof of the Arrhenius Laboratory at
Stockholm University, 20 m above the ground, in the cen-
tre of Stockholm. The pollen count is expressed as the
mean number of pollen grains per day and per cubic
metre of filtered air, at two-hour intervals during the day.
The pollen counts during the two seasons were compara-
ble, in terms of both the pollen peak and the duration of
the season (Figure 1).
Skin prick tests
were performed with nine standard aeroallergen extracts
(birch, timothy, mugwort, cat dander, dog dander, horse
dander, Dermatophagoides pteronyssinus, Cladosporium her-
barum  and  Alternaria), using Soluprick SQ ALK (Hör-
sholm, Denmark). The results were read after 15 minutes,
measuring the largest diameter of the weal and its perpen-
dicular diameter, and the product was expressed in mm2.
Skin reactions were considered positive when larger than
9 mm2.
Spirometry
Lung function tests were performed with a Vitalograph-
Compact spirometer, (Vitalograph Ltd., Buckingham,
England). FEV1, FVC, FEV1/FVC% and PEFR were
recorded. The reference values were those from European
Community for Coal and Steel [21]. Peak flow rate (PEFR)
values were measured by the subjects in the morning and
in the evening during the pollen season using a mini-
Wright Peak Flow Meter (Clement Clarke International
Ltd., Essex, England) and recorded in the diary.
Nasal lavage
Lavage of the nasal mucosa was performed according to
Wåhlinder et al. [22] with a 20-ml syringe attached to a
nose olive. The subjects stood, with their heads flexed
about 30° forward. At room temperature (20–22°), ster-
ile 0.9% saline was introduced into the nasal cavity. Each
nostril was lavaged with 5 ml of the solution, which was
flushed back and forth five times via the syringe, at inter-
vals of a few seconds. The recovered fluid was weighed
and the amounts obtained were comparable in all sub-
jects. The fluid was transferred into 10-ml polypropylene
centrifuge tubes. It was kept on ice and, within 300 min-
utes, the solution was centrifuged at 800 g for five min-
utes. The supernatant was then centrifuged at 1,400 g for
five minutes and immediately frozen in small aliquots to
-70°C for analyses of eosinophilic cationic protein (ECP)
and human neutrophil lipocalin (HNL). The cell suspen-
sion was concentrated in object glasses using cytospin
centrifugation for differential counting.
Induced sputum
Sputum samples were obtained by hypertonic saline inha-
lation modified after Pizzichini et al. [23,24], except that
the subjects were not pretreated with inhaled bronchodi-
lators. FEV1 was measured before and after the inhalation
of physiological saline and induction was then started
with hypertonic saline solution. An ultrasonic nebuliser
(OMRON U 1, Sonesta Tamro no 28 36 06, Stockholm,
Sweden) was used for the inhalations. FEV1 was measured
before and 90 seconds after inhalation of physiologic
saline. Then hypertonic (4.5%) saline solution was
administered for 0.5, 1, 4, 8 and 16 minutes. FEV1 was
recorded 90 seconds after each inhalation. The subjects
were asked to rinse their mouths with water and then to
cough sputum into a sterile container. The test was
stopped if FEV1 fell with 20% or more compared with the
value obtained after inhaling isotonic saline. After com-
pleting the inhalation, the subjects were instructed to
"huff" and cough into the container. The mucus clods
were aspirated with a 2-ml syringe and collected. The
entire sputum clod was weighed and immediately trans-
Pollen counts, grains/m3, during the birch pollen season in  2000 and 2002 Figure 1
Pollen counts, grains/m3, during the birch pollen season in 
2000 and 2002.
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Table 1: Study design.
Visit 1 Inclusion Visit 2 Baseline 
out of season
Visit 3 Birch 
pollen season
Blood sample x x x
Spirometry x x x
Skin prick test x
Specific IgE for 
birch
x
Nasal lavage x x
Induced sputum x x
Diary
- symptoms x
- medication x
- PEFR x
x: performed investigations at each visitClinical and Molecular Allergy 2007, 5:4 http://www.clinicalmolecularallergy.com/content/5/1/4
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ported to the laboratory. The sputum sample was kept on
ice and an equal amount of 0.2% dithiothreitol in phos-
phate buffer, sputolysin (CalbioChem, SputolysinRea-
gent, art no 56000), was added before incubation at 22°C
for 15 minutes. The sample was then centrifuged and the
supernatant frozen at -70°C for the subsequent analysis of
ECP and HNL. The cell suspension was concentrated on
object glasses using cytospin centrifugation for differential
cell counting.
Cell count and specific inflammatory markers
Four ml of EDTA blood was collected for routine labora-
tory tests of eosinophil counts (Cell-Dyn 4000, Abbott).
Serum for analyses of ECP and HNL was collected from
the four ml of blood in SST tubes (Becton Dickinson AB),
kept for 60 minutes in room temperature and centrifuged
for 10 minutes at 3600 rpm. The serum was frozen to -
70°C.
Blood eosinophil counts (B-Eos) (normal range 0.0–0.5 ×
109/l) were determined using routine methods at the
Department of Clinical Chemistry, Uppsala University
Hospital. Differential cell counts were obtained using a
cytospin preparation (Cytospin, Shandon, Southern
Instruments, Sewickley, USA) stained with May Grüne-
wald and Giemsa, and examined under light microscope.
ECP was analysed by Unicap, Pharmacia. HNL was
assayed by a double-antibody RIA described in detail else-
where [25]. The inter- and intra-assay coefficients of vari-
ations were < 10% for all tests. Specific IgE was
determined with a RadioAllergoSorbent Test (RAST) at the
Department of Clinical Immunology, Uppsala University
Hospital (normal < 0.35 kU/L).
Diary
Starting two weeks prior to the season visit, the subjects
with allergic rhinitis and allergic asthma recorded their
morning PEFR and evening PEFR every day. The highest
value of three was registered in the diary.
Symptoms were graded from 0 to 3 (none to severe) for
each symptom: rhinitis, conjunctivitis and respiratory
symptoms (shortness of breath, chest tightness, cough)
during the day and night. A symptom score was con-
structed for rhinoconjunctivitis by adding the nose and
eye score each day divided by two. The daytime and noc-
turnal respiratory score was combined in the same way. A
total score for the four symptoms was also calculated. A
mean symptom score for each subject was calculated from
the sum of symptoms, divided by the number of regis-
tered days.
Medication was recorded in the diary. The following med-
ication categories were used: oral anti-histamine, topical
treatment in the nose and eyes (anti-histamines and/or
cromones) and inhaled short-acting beta-agonists during
the day and night. The number of drugs in each category
was calculated for each day and divided by the number of
registered days and a total medication score was generated
by combining all the categories.
Ethics committee
The study was performed with the approval of the ethics
committee at the Medical Faculty at Uppsala University
and informed consent was obtained from each subject.
Statistical evaluation
The Kruskal-Wallis, ANOVA and Mann-Whitney U test
were used to evaluate statistical differences between
patient groups. For paired analyses, we used Friedman's
ANOVA and Wilcoxon's matched pairs test. A p-value of <
0.05 was considered significant. All the calculations were
performed using the Statistica statistical software package
(Statsoft Inc, Tulsa, Oklahoma, USA).
Results
No significant differences concerning sex, age or smoking
were found between the three groups of test persons.
There were no differences in allergy variables between the
two groups of allergic patients. (Table 2).
Lung function, medication and symptoms
At baseline no significant difference was found regarding
lung function (Table 2), except that patients with allergic
asthma had a significantly larger decline in FEV1 after
inhaling hypertonic saline solution (median (IQ range): -
7.0 (-9.4, -1.6)%) than patients with allergic rhinitis (-0.4
(-4.1, 4.0)%) or controls (1.1 (-0.5, 8.2)%) (Figure 2).
Table 2: Characteristics at baseline (mean, range). No significant 
differences were found between any of the groups in terms of 
gender, age, smoking and lung function or between the two 
allergic groups in terms of allergy variables.
Control group 
(n = 5)
Allergic 
rhinitis (n = 9)
Allergic asthma 
(n = 7)
Gender 
(male/female)
2/3 8/1 5/2
Age 38 (27–58) 43 (24–66) 44 (27–56)
Ex-smokers 0 2 1
SPT birch mm2 0 47.1 (20–88) 43.6 (26–64)
Specific IgE for 
birch kU/L
0 3.1 (2–4) 3.4 (2–5)
*Number of 
positive SPT
0 4 (0–4) 5 (1–6)
FEV1 (L) 3.59 (3.02–3.95) 4.0 (2.4–4.9) 3.41 (2.56–3.97)
FEV1 
(% of predicted)
105 (88–125) 102 (75–139) 96 (83–108)
PEFR (L/min) 571 (348–854) 615 (415–826) 506 (347–652)
PEFR 
(% of predicted)
117 (84–169) 113 (82–140) 100 (73–133)
* In addition to birchClinical and Molecular Allergy 2007, 5:4 http://www.clinicalmolecularallergy.com/content/5/1/4
Page 5 of 8
(page number not for citation purposes)
The group with allergic asthma had a significantly lower
morning and evening PEFR during the birch pollen sea-
son (Table 3). No significant difference was found
between the groups regarding symptoms or treatment for
rhinoconjunctivitis. No significant changes in ΔFEV1
(change in % in FEV1  compared with before-season
spirometry) could be seen during the pollen season in any
of the allergic groups (Table 3).
Inflammation
No significant differences in inflammatory markers in
blood, nasal lavage or induced sputum were found
between any of the groups at baseline, except for a signif-
icantly higher value for nasal lavage (NL) -ECP in the rhin-
itis group compared with the control group (p = 0.045)
(Table 4).
During the birch pollen seasons there were significant
increases in B-Eos and sputum (Sp) ECP in the rhinitis
and asthma groups but not in the control group (Table 5,
Figure 3). The ΔNL-Eos was significantly larger in the rhin-
itis than in the control group (Table 5, Figure 3). Signifi-
cantly larger decreases in both ΔNL-HNL and ΔSp-HNL
were found in the group of subjects with predominant
rhinitis than in the control group (Table 5). There were no
differences between the two groups of allergic patients
regarding the changes in inflammatory parameters during
the pollen seasons.
Discussion
The main finding in our study is that birch pollen allergic
patients with either rhinitis or asthma as predominant
expression of their disease have comparable levels of eosi-
nophil inflammation in the blood, nose and lower air-
ways both before and during the pollen season. Our
results highlight the close relationship between the upper
and lower airways in both allergic diseases and support
the concept of "one airway – one disease" [26,27]. The
results we obtained during seasonal allergen exposure are
in accordance with the results of studies using allergen
challenges, where Braunstahl et al. showed that both nasal
provocation and segmental bronchial allergen challenge
induce inflammation in both bronchial and nasal
mucosa, i.e. the link is bi-directional [9,10]. Nasal aller-
gen challenge tests have also produced data supporting
the concept of "allergy syndrome", showing eosinophil
inflammation in the oesophagus [28], and other studies 
Table 4: Baseline inflammatory parameters in blood, nasal lavage 
and induced sputum (median, upper and lower quartiles) (* = p < 
0.05 compared with the control group)
Control group Allergic rhinitis Allergic asthma
Blood
B-eosinophils 
109/L
0.12 (0.10, 0.13) 0.1 (0.08, 0.17) 0.14 (0.11, 0.21)
S-ECP μg/L 8.6 (5.5, 9.4) 9.0 (6.2, 11.8) 6.1 (4.4, 11.3)
S-HNL μg/L 89 (56, 105) 93 (84, 99) 99 (65, 118)
Nasal lavage
Eosinophils% 0 (0, 0) 0.1 (0–0.4) 0.3 (0, 0.5)
ECP μg/L 2 (2, 2) 3 (2, 13)* 2 (2, 5)
HNL μg/L 30 (26, 33) 74 (65, 176) 83 (40, 202)
Sputum
ECP μg/L 149 (81, 280) 192 (126, 403) 146 (54, 350)
HNL μg/L 1724 (636, 
2570)
839 (573, 1854) 1606 (480, 2357)
Difference in ΔFEV1 (change in FEV1 compared to baseline  FEV1) between allergic rhinitis and allergic asthma after inhal- ing hypertonic saline solution (4.5%) at baseline Figure 2
Difference in ΔFEV1 (change in FEV1 compared to baseline 
FEV1) between allergic rhinitis and allergic asthma after inhal-
ing hypertonic saline solution (4.5%) at baseline.
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Table 3: Diary recorded during birch pollen season (median, 
upper and lower quartiles).
Allergic rhinitis Allergic asthma p-value
Symptom score
Nose and eyes 2.4 (1.1, 3.9) 3.8 (1.9, 4.9) 0.37
Respiratory 1.3 (0, 4.2) 1.3 (0.4, 2.0) 0.83
Total 3.8 (2.4, 6.7) 4.2 (3.0, 6.9) 0.67
Medication score
Oral anti-histamine 1 (1, 1) 1 (0, 1.1) 0.67
Topical * 1.75 (0.25, 2) 0.9 (0, 2.6) 0.83
Beta-2-agonists 0 (0, 0) 0.6 (0.2, 1.9) 0.006*
Total 3 (1.2, 3.5) 2.7 (0.5, 5.6) 0.79
Lung function
Morning PEFR 
(L/min)
575 (550, 620) 475 (433, 551) 0.020
Evening PEFR 
(L/min)
610 (555, 630) 478 (449, 551) 0.005
ΔFEV1 ** -0.07 (-0.37, 0.2) -0.21 (-0.43, -0.16) 0.26
* Topical medication: anti-histamines and/or cromones
** Change in FEV1 in % compared with before-season spirometryClinical and Molecular Allergy 2007, 5:4 http://www.clinicalmolecularallergy.com/content/5/1/4
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have showed eosinophil inflammation in the stomach
and small intestine during the pollen season, despite a
lack of gastrointestinal symptoms [29].
In spite of the fact that both groups of allergic patients had
a similar inflammation pattern, distinct differences were
found between the groups. The patients with predomi-
nant asthma had a higher bronchial responsiveness when
measured with hypertonic saline challenge, a lower PEFR
during the season and were much more likely to use β2-
agonists than patients with predominant rhinitis. On the
other hand, both groups had the same degree of rhinoc-
onjunctivitis and used the same amounts of oral antihis-
tamines and local treatment in eyes and nose. Our data
partly disagrees with that of Ciprandi et al. [30], who
found a decrease in FEV1 during the pollen season in rhin-
itis patients, whereas, in Ciprandi's study, patients show-
ing early bronchial impairment and BHR patients with
perennial rhinitis and diagnosed BHR were included.
The eosinophil inflammation in different compartments,
measured as the number of eosinophils as well as the con-
centration of ECP, was comparable between the two aller-
gic groups. In both groups, a significant increase was
found in B-Eos and Sp-ECP compared with the non-aller-
gic controls, whereas no distinct pattern was found when
it came to neutrophil inflammation. The role of neu-
trophils in mild asthma and allergic rhinitis is uncertain,
whereas in severe asthma neutrophils play an important
role in the pathogenesis of airway inflammation [31]. Our
data confirm that there is an eosinophil inflammation in
both the nasal and bronchial mucosa and systemically in
both allergic asthma and allergic rhinitis during the pol-
len season. However, in spite of the same level of eosi-
nophil inflammation in the lower airways, only the
asthmatic group present with significant BHR and impair-
ment of lung function during the pollen season. These
Blood eosinophil counts (A), Percentage of eosinophils in  nasal lavage (B) and sputum ECP (C) increase during pollen  season in both allergic rhinitis and patients with allergic  asthma Figure 3
Blood eosinophil counts (A), Percentage of eosinophils in 
nasal lavage (B) and sputum ECP (C) increase during pollen 
season in both allergic rhinitis and patients with allergic 
asthma.
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Table 5: Changes in inflammatory parameters in blood, nasal lavage and induced sputum between baseline out of season and during 
birch pollen season (median, upper and lower quartiles).
Control group Allergic rhinitis p-value Allergic asthma p-value
Blood
Δeosinophils 109/L 0.01 (0, 0.025) 0.27 (0.17, 0.43) 0.014* 0.17 (0.03, 0.27) 0.012*
ΔS-ECP μg/L 2,3 (0.5, 2.4) 9.6 (4.9, 16.1) 0.071 8.6 (-0.2, 11.5) 0.12
ΔS-HNL μg/L 19.1 (4.7, 31.4) 1.8 (-3.5, 5.3) 0.20 1,7 (-1.0, 14.4) 0.12
Nasal lavage
Δeosinophils % 0.05 (0, 0.1) 6.7 (1.9, 28.8) 0.007* 23.3 (2.3, 57.8) 0.055
ΔECP μg/L 0 (0, 5) 1.4 (-0.1, 5.8) 1.0 4 (0, 10.1) 0.29
ΔHNL μg/L 85 (45, 109) -17 (-44, 21.9) 0.039* -10 (-28.8, 24.8) 0.22
Sputum
ΔECP μg/L -146 (-163, 0.3) 310 (19, 2000) 0.019* 2180 (12, 2480) 0.018*
ΔHNL μg/L -766 (-1655, 302) 46 (-340, 190) 0.040* -218 (-1084, 748) 0.17Clinical and Molecular Allergy 2007, 5:4 http://www.clinicalmolecularallergy.com/content/5/1/4
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data are consistent with reports from other groups
[32,33], indicating that other factors, such as airway
remodelling, play a role in the development of BHR in
asthma. Boulay et al. also demonstrated an increase in
eosinophils in induced sputum after repeated very-low-
dose allergen challenge in allergic rhinitis, without any
changes in FEV1 or response to metacholine challenge
[19].
The strength of our study is that we have evaluated the
nasal and bronchial inflammation in the same patients
simultaneously. Another advantage is that we have used
natural exposure to allergens. Allergen exposure during
the pollen season is a low-dose challenge over a long
period and is more like the natural course of allergy devel-
opment than high-dose allergen challenge. It is known
from both experimental studies and real life that very high
doses of allergen can elicit asthma symptoms in non-asth-
matics, if the doses are high enough [34]. The Swedish
birch pollen season is very convenient to study, as it is rel-
atively short and defined in time and comes after a long,
cold winter, making it a suitable model for seasonal
allergy studies. Usuallay the birch pollen season varies in
pollen counts, with high pollen counts every second year.
One drawback of this study is the small number of sub-
jects in each group, which limited the opportunity to find
differences between the two allergic groups.
In conclusion allergic asthma and allergic rhinitis have the
same degree of eosinophil inflammation in blood, nasal
mucosa and bronchial mucosa during the pollen season.
In spite of this, only the asthmatic group present with sig-
nificant BHR and impairment of lung function during the
pollen season. This indicates that eosinophil inflamma-
tion in the bronchial mucosa alone is not enough to cause
asthma and that factors other than eosinophil inflamma-
tion determine whether or not an allergic patient develops
asthma.
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